The results of the AURA3 trial, a phase III trial comparing osimertinib with platinum and pemetrexed for patients with non-small cell lung cancer (NSCLC) harboring the EGFR T790M mutation who were previously treated with EGFR-TKIs, were reported in 2017 [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.